“Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in mechanically ventilated patients with infectious pulmonary endotheliopathy – a multicentre randomized, placebo-controlled, blinded, investigator-initiated trial” (COMBAT-ARF).

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512641-16-00

Enrollment

450

Registered

2024-03-25

Start date

2024-04-15

Completion date

Unknown

Last updated

2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious pulmonary endotheliopathy

Brief summary

28-day all cause mortality

Detailed description

90-day mortality, Days alive without vasopressor in the ICU within 28-and 90 days, Days alive without mechanical ventilation in the ICU within 28 -and 90 days, Days without renal replacement in the ICU within 28-and 90 days, Numbers of serious adverse reactions within the first 7 days, Numbers of serious adverse events within the first 7 days

Interventions

DRUGNatriumklorid ”B. Braun”

DRUGIlomedin

DRUGkoncentrat til infusionsvæske

DRUGopløsning

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
28-day all cause mortality	—

Secondary

Measure	Time frame
90-day mortality, Days alive without vasopressor in the ICU within 28-and 90 days, Days alive without mechanical ventilation in the ICU within 28 -and 90 days, Days without renal replacement in the ICU within 28-and 90 days, Numbers of serious adverse reactions within the first 7 days, Numbers of serious adverse events within the first 7 days	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026